24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
EMPALIEVA 25 MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | EMPALIEVA 25 MG |
|---|---|
| Composition | Empagliflozin Tablets 25mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | 10x10 |
| Country of Origin | India |
EMPALIEVA 25 MG (Empagliflozin Tablets 25mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
EMPALIEVA 25 MG (Empagliflozin Tablets 25 mg) is a prescription medicine containing Empagliflozin 25 mg, an oral antidiabetic medication belonging to the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor class. It is primarily used to improve blood sugar control in adults with Type 2 Diabetes Mellitus and is also associated with cardiovascular and kidney health benefits in appropriate patients.
Empagliflozin works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and increasing the elimination of excess glucose through urine. This helps lower blood glucose levels independently of insulin while also supporting modest weight reduction and blood pressure control in many patients.
EMPALIEVA 25 MG is commonly prescribed along with a healthy diet and regular exercise for adults with Type 2 Diabetes Mellitus. It may be used alone or in combination with other antidiabetic medicines as recommended by a healthcare professional.
The medicine is taken orally and should be used exactly as prescribed by a qualified healthcare provider.
EMPALIEVA 25 MG is commonly used for:
Manufactured according to stringent pharmaceutical quality standards, EMPALIEVA 25 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Empagliflozin therapy should undergo regular monitoring of blood glucose levels, kidney function, and overall health during treatment.
EMPALIEVA 25 MG (Empagliflozin Tablets 25 mg) is primarily used in the treatment and long-term management of Type 2 Diabetes Mellitus.
Helps improve blood sugar control when combined with diet and exercise.
Reduces elevated blood glucose by increasing urinary glucose excretion.
May reduce the risk of cardiovascular events in eligible adults with Type 2 Diabetes and established cardiovascular disease.
May be prescribed to reduce hospitalization for heart failure in selected patients.
May help slow the progression of kidney disease in appropriate patients as advised by a physician.
Can be used with metformin, insulin, DPP-4 inhibitors, or other antidiabetic medicines.
Supports comprehensive diabetes management alongside lifestyle modifications.
Empagliflozin belongs to the SGLT2 Inhibitor class of medicines.
EMPALIEVA works by:
This mechanism helps improve glycemic control while providing additional health benefits in selected individuals.
Like all medicines, EMPALIEVA 25 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Increased urination is common due to higher glucose excretion.
Some patients may develop urinary tract infections.
Yeast infections may occur in both men and women.
Patients may feel thirstier than usual.
Dizziness may occur due to fluid loss, especially in elderly patients.
Adequate fluid intake is important during treatment.
Some patients may experience modest weight reduction.
Changes in lipid profile may occur in some individuals.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of EMPALIEVA 25 MG (Empagliflozin Tablets 25 mg) should always be determined by a qualified healthcare professional.
Dosage depends on glycemic control requirements.
Renal function should be evaluated before and during treatment.
Concomitant antidiabetic medicines may influence therapy.
The patient's clinical condition determines treatment planning.
Dose adjustments may be considered based on therapeutic response.
Before starting treatment, inform your doctor if you have:
Patients receiving Empagliflozin therapy may require:
Patients should also disclose all prescription medicines, supplements, vitamins, and herbal products they are taking to avoid potential drug interactions.
Pregnant and breastfeeding women should use this medicine only if specifically advised by a healthcare professional.
It is used to improve blood sugar control in adults with Type 2 Diabetes Mellitus and may also provide cardiovascular and kidney benefits in appropriate patients.
Empagliflozin is an SGLT2 inhibitor that lowers blood sugar by helping the kidneys remove excess glucose through urine.
No. It is generally not indicated for the treatment of Type 1 Diabetes unless specifically advised by a specialist.
Some patients may experience modest weight loss during treatment.
Yes. Increased urination is a common effect because the medicine removes excess glucose through urine.
Yes. It is often used in combination with other antidiabetic medications as prescribed by a healthcare professional.
Yes. Routine monitoring of blood glucose, kidney function, and overall health is recommended.
Yes. This medicine should only be used under the guidance of a qualified healthcare professional.